NCT04114630 - Study of Quality of Life in Subjects With Chronic or High-frequency Episodic Migraine and Associated Comorbidities Treated With Erenumab | Biotech Hunter

Timeline

Start Date

October 30, 2019

Primary Completion Date

December 6, 2021

Study Completion Date

January 7, 2022

Conditions

Migraine

Interventions

DRUG

erenumab 70mg/mL

Unit dose: 70 mg/mL single-dose., prefilled erenumab autoinjectors. 140 mg dose = 2 x 70 mg/mL, single dose, prefilled erenumab autoinjectors

Trial Locations (27)

11009

Novartis Investigative Site, Cadiz

14011

Novartis Investigative Site, Córdoba

15706

Novartis Investigative Site, Santiago de Compostela

27003

Novartis Investigative Site, Lugo

28003

Novartis Investigative Site, Madrid

28006

Novartis Investigatice Site, Madrid

28040

Novartis Investigative Site, Madrid

28046

Novartis Investigative Site, Madrid

28223

Novartis Investigative Site, Pozuelo de Alarcón

28922

Novartis Investigative Site, Alcorcón

28942

Novartis Investigative Site, Fuenlabrada

31008

Novartis Investigative Site, Pamplona

38010

Novartis Investigative Site, Santa Cruz de Tenerife

41009

Novartis Investigative Site, Seville

41013

Novartis Investigative Site, Seville

46010

Novartis Investigative Site, Valencia

46026

Novartis Investigational Site, Valencia

47005

Novartis Investigative Site, Valladolid

48013

Novartis Investigative Site, Bilbao

48903

Novartis Investigative Site, Barakaldo

50009

Novartis Investigative Site, Zaragoza

07120

Novartis Investigative Site, Palma de Mallorca

08003

Novartis Investigative Site, Barcelona

08035

Novartis Investigative Site, Barcelona

08041

Novartis Investigative Site, Barcelona

08907

Novartis Investigative Site, L'Hospitalet de Llobregat

03600

Novartis Investigative Site, Elda